Objectives. To evaluate the effect of autologous stem cell transplantation (aSCTrans) on antibody (Ab) reactivity towards topo I in patients with SSc, and to see whether it may correlate with clinical outcome after aSCTrans.
Introduction
SSc in its diffuse cutaneous variant has the worst outcome of any of the CTDs. There are hardly any therapeutic options for general improvement or termination of fibrosis [1] . For refractory autoimmune diseases in general, in recent years autologous stem cell transplantation (aSCTrans) has emerged as a treatment option; because of its dismal prognosis, SSc in particular was considered a good target for this therapy (for literature survey see [2, 3] ), although it is associated with potentially life-threatening side effects, notably involving heart and lungs [4, 5] . However, there are still only few and controversial studies analysing the immune reconstitution in SSc patients treated with aSCTrans [6, 7] .
SSc is characterized by autoantibodies, notably to DNA topo I, RNA polymerases I, II and III, and centromere/kinetochore. Antitopo I antibodies (Abs), formerly termed antiScl-70, are present in 2030% of SSc patients and are preferentially associated with diffuse cutaneous involvement and pulmonary interstitial fibrosis, indicating an unfavourable course [8] . Topo I is synthesized as a precursor with a molecular weight of 100 kDa, which is then proteolytically processed to a 70 kDa protein, from which the Scl-70 antigen has derived its name. Several epitopes are recognized by antitopo I Abs, and the epitope amino acids (aa)489573 in particular have been shown to be an immunodominant site [9] . The behaviour of these topo Irelated Abs after aSCTrans had not yet been analysed in detail, and there was also no knowledge about their correlation with the clinical outcome after aSCTrans. The aim of the present study was, therefore, to examine the influence of aSCTrans on autoantibody reactivity towards topo I in SSc patients, in order to see whether they may correlate with the clinical outcome after aSCTrans.
Patients
Recently we presented 26 [10] and 6 patients [11] patients with dcSSc scheduled for aSCTrans as a rescue therapy [10] . Detailed clinical data have been previously described [10, 11] . Significant lung function improvement and reduction of the modified Rodnan skin score (mRSS) was achieved in 78.3 and 66.6% of patients in month 6, respectively [10, 11] . The overall response rate was 91%, as some patients improved even after month 6.
Eighteen of these patients had anti-Scl70/topo Abs; only these patients were included in the present study (11 females, 7 males, mean age 38.2 years, range 1957 years; mRSS 15.5) (supplementary Table S1 , available at Rheumatology Online). The study was approved by the local ethics committee (Ethik-Kommission an der Medizinischen Fakultä t der Eberhard-Karls-Universitä t und am Universitä tsklinikum Tü bingen); it was performed according to the Declaration of Helsinki guidelines, and patients provided written informed consent before the study.
Diagnosis had been re-evaluated according to the 2013 Classification Criteria for SSc [12] . Exclusion criteria for aSCTrans, clinical and biochemical data, treatment and outcome measures have been recently described [10, 11] . Briefly, all patients either had an inadequate response to CYC or rapidly progressive diffuse disease and indicators of poor prognosis. The main exclusion criteria were a Karnofsky index of < 70%, and pulmonary arterial hypertension with systolic pulmonary oxide [diffusing capacity for carbon monoxide (DLCO); of predicted values] of <40%. The transplant regimen consisted of mobilization with i.v. CYC (2 Â 2 g/m 2 or 2 Â 1 g/m 2 ) and G-CSF followed by leukapheresis and CD34 selection of the autologous graft. Conditioning was performed with i.v. CYC (4 Â 50 mg/kg body weight) and rabbit anti-thymocyte globulin (ATG) (4 Â 10 mg/kg), or with CYC (2 Â 50 mg/ kg body weight), rabbit ATG (4 Â 10 mg/kg) and thiotepa (2 Â 5 mg/kg body weight) in patients with cardiac involvement [11] .
Response to treatment was defined as 25% improvement of the mRSS at month 6 or 12; relapse was defined as any worsening of the mRSS or >10% drop in forced vital capacity (FVC) and/or a >15% drop in DLCO (of predicted values), with new ground-glass pattern in CT scans after transplantation. These definitions are in accordance with the recently published data of the European Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial [3] .
Fourteen patients showed significant improvement after aSCTrans, five of whom experienced a mild relapse during a long-time follow-up of 81 months; two patients did not respond, and two patients developed a severe relapse of SSc after a primary response (months 5 and 23, respectively) and died because of pulmonary and cardiac complications (supplementary Table S1 , available at Rheumatology Online). All other patients are still alive. Altogether, a significant reduction of the mRSS was observed 6 months after aSCTrans, from a median of 15.5 to a median of 8.0 (P < 0.01).
Patients were classified according to the outcome after aSCTrans as patients with a good response and no relapse (group 1, n = 7), versus those with primary response but relapse or without response (group 2, n = 11) during a long-time follow-up of 81 months [10] . From all 18 patients, sera were available before transplantation [time point (tp) 0]; five tps after aSCTrans were chosen (see Figs 1 and 2). In total, 74 sera were analysed. As controls, sera from 21 healthy individuals (kindly provided by Dr D. Wernet, Institute for Transfusion, Tuebingen) were included in the study (15 females, 6 males; mean age 44 years, range 2163 years).
Methods

Methods for detection of autoantibodies
ELISA
Antigens used in the ELISA. Full-length (topofl) and truncated (topotr; aa191765) topo Is, and the epitope 489573 (topo489573) were obtained from Diarect, Freiburg, Germany.
Performance of ELISA. Abs were detected by ELISA by published in-house assays [13] . Briefly, 96-well microtitre plates (Nunc Maxisorp; Thermo Fisher Scientific, Waltham MA, USA) were coated with topofl or topotr at a concentration of 1 mg/ml, and with topo489573 at a concentration of 0.1 mg/ml. Patients' sera were diluted 1:1000. Bound Abs were detected with peroxidase-conjugated antihuman IgG Abs and IgM Abs in parallel (DIANOVA, Hamburg, Germany; dilution 1:2000). All tests were performed in duplicates.
For all antigens, optimal antigen and serum dilutions had been evaluated by serial dilutions prior to the study. Specificity and sensitivity were 95 and 69%, respectively, for both topofl and topotr, testing a large series of patients with various collagen disorders and also healthy controls (data not shown). The in-house assays had been validated by commercial kits.
Radial immunodiffusion
Precipitating Abs to ENA from calf thymus were determined by radial immunodiffusion [14] . AntiScl70positive marker sera had been primarily provided by the American Center of Disease Control, Atlanta, and have been substituted in past years with our own marker sera.
Statistics
For statistical analysis, SPSS version 15.0 was used. Fisher's exact test was applied for comparing prevalence; for comparing paired data, KruskalWallis analysis was performed; for comparing unpaired data. MannWhitney U tests were performed. P < 0.05 was considered statistically significant. Correlation was evaluated by determination of the Pearson correlation coefficient. Normal values against the various antigens in the ELISA were determined with sera from 21 healthy controls; the means of their absorbance (Â1000) + 3-fold standard deviations were taken as the upper limits of the normal range.
Results
Reactivity of patients' sera with topo I before and after aSCTrans, and correlation with the clinical outcome after aSCTrans
Topofl and topotr
Of the 18 SSc patients, 15 had IgG and 5 had IgM Abs to topofl before aSCTrans, as tested by ELISA; 3 (patient nos 17, 21 and 22) had only precipitating anti-Scl70 Abs in the immunodiffusion (supplementary Tables S1 and S2, available at Rheumatology Online). Prevalence of IgG Abs did not change significantly after aSCTrans, while the IgM Abs became negative (supplementary Table S2 , available at Rheumatology Online). Ab reactivity towards topofl and topotr strongly correlated (for IgG r = 0.99; for IgM r = 0.85).
After aSCTrans, reactivity of both IgM and IgG Abs towards topofl and topotr decreased at the whole-group level (Fig. 1) , although in some patients (for instance nos 5, 9) Ab reactivity was not at all affected; in only one patient (no. 4), IgG reactivity to topofl became negative, while IgM-antitopofl reactivity became negative in all patients. The three sera that were anti-Scl70 positive in the ID but anti-topo negative in the ELISA before aSCTrans (nos 17, 21 and 22) developed no anti-topo Abs after aSCTrans, as expected.
Before aSCTrans, anti-topo reactivity was higher in patients of group 2 (primary response but relapse, or no response) than in those of group 1 (good response), but the difference was not statistically significant (P = 0.08; shown for topofl in supplementary Fig. S1 , available at Rheumatology Online). In both groups it significantly decreased within the first months after aSCTrans, without reaching statistical significance. Anti-topofl reactivity before aSCTrans did not correlate with the mRSS before or 6 months after aSCTrans or the percentage improvement of the mRSS (data not shown).
Immunodominant epitope topo489573
Of the 15 anti-topopositive patients, 14 could be analysed for Abs against topo489573. Ten of them (71%) had IgG Abs and one (7%) had IgM Abs against topo489573. There was only a weak correlation between anti-topo489573 and anti-topofl reactivity (r = 0.46) or anti-topotr reactivity (r = 0.48).
The prevalence of IgG Abs to topo489573 decreased after aSCTrans, from 71% at tp 0 to 50% at tp 3 (>19 months) (data not shown). Also, their reactivity significantly decreased; again, in Patient No. 5, Ab reactivity was not affected.
When comparing patients with a good response (group 1) and patients with a relapse or no response (group 2), patients of group 2 showed significantly higher IgG reactivity towards topo489573 than patients of group 1 (Fig. 2) . In group 2 patients, Ab reactivity significantly decreased during the first months after aSCTrans. In contrast, anti-topo489573 activity before aSCTrans did not correlate with the mRSS before or 6 months after aSCTrans, or the percentage improvement of the mRSS (data not shown).
Discussion
To our knowledge, this is the first study analysing autoantibody reactivity towards different topo Irelated antigens, including peptides, in a large number of patients with SSc who underwent aSCTrans. Although Ab reactivity towards topofl, topotr and the immunodominant epitope 489573 decreased after aSCTrans, it still remained strongly positive in most patients. Interestingly, antitopo489573 reactivity was significantly higher in patients with relapse or no response after aSCTrans as compared with patients with good response. This difference was not observed when the entire topo I proteins were applied as antigens. Of the 18 patients analysed, 15 (83%) had Abs to recombinant topofl or topotr in the ELISA, while three had only precipitating anti-Scl70 Abs, in accordance with previous reports that at least some SSc patients have Abs reacting with conformational epitopes [9] . Moreover, as already known [15] , the Abs were preferentially of the IgG type; only $25% had IgM Abs. Application of topo489573 as the antigen in the ELISA showed less sensitivity for SSc than topofl or topotr. Thus, it was recognized by only 71% of the anti-topopositive sera.
Introduction of aSCTrans as treatment for progressive SSC [2, 3]-and also for other autoimmune disorders-was based on the concept that it may lead to an 'immune reset' by eradication of auto-reactive lymphocytes by immunoablative conditioning, and/or the correction of a dysregulated immune balance by newly developed (regulatory?) lymphocytes derived from transplanted haematopoietic stem cells [7, 16] . There are only few studies in small cohorts of SSc patients analysing immune reconstitution after aSCTrans. Thus, a reduction in CD4 + T cells and B cells, a shift from Th2 to Th1 cells, and a suppression of serum autoantibody and cytokine concentrations have been described [6, 7, 17] . In contrast, Storek et al. [18] showed that the level of anti-Scl70 Abs remained abnormally high throughout the 24 months after aSCTrans. This is in accordance with our own data; although antitopo I Abs decreased significantly after aSCTrans, they remained strongly positive in most of the patients. This may either indicate that aSCTrans did not lead to re-programming of the immune system, at least in these patients, that the CD34 + progenitor cells reinfused may be prone to differentiate again into autoreactive cells directed against topo I antigens, or that the kind of treatment was insufficient to eliminate the autoreactive cells, including long-living plasma cells still producing autoantibodies. We also analysed whether the persistence of Abs to topofl or topotr or their reappearance may correlate with the failure to respond or a relapse of the disease after aSCTrans, but there was no evidence for this. In contrast, Ab reactivity to the immunodominant epitope489573 was significantly higher in patients with relapse-even with mild relapse-or no response than in patients with good response towards this therapy; but there was no correlation between Ab reactivity to topofl or topo489573 and mRSS or percentage mRSS improvement after aSCTrans.
In conclusion, although aSCTrans is a potent treatment modality for selected SSc patients, there is no evidence that it has strong effects on the (humoral) autoreactivity in these patients. This, again, clearly emphasizes the need for more intensive studies on reconstitution and 'rebooting' of the immune system after aSCTrans. Whether the presence of anti-topo489573 Abs before aSCTrans may be taken as a biomarker predicting relapses after aSCTrans is yet to be proven in prospective studies. L.G.: performance of experiments, acquisition, analysis and interpretation of data, revising the article; I.K., W.V., L.K.: acquisition of patients, analysis of data, revising the article; R.K.: experimental design of the study, analysis, interpretation of data, drafting the article. All authors approved the final version of the manuscript.
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FIG. 2 Antitopo I reactivity against the immunodominant epitope 489573 in SSc patients before and after autologous stem cell transplantation IgG antibody reactivity towards the immunodominant epitope topo489573 in 14 anti-topoflpositive patients with SSc before (time point 0) and after autologous stem cell transplantation in relation to the response to this kind of therapy (group 1: good response; group 2: primary response but relapse or no response). Time point 1: patients followed for 19 months after aSCTrans, time point 2: patients followed for 1018 months, time point 3: patients followed for 519 months. Mean values and S.D.'s are given. Patients in group 2 had significantly higher anti-topo489573 reactivity (*P = 0.02) than patients in group 1.
